A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Study identifier:D9230C00001

ClinicalTrials.gov identifier:NCT05143905

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 Following Single Ascending Dose Administration to Healthy Participants

Medical condition

Safety, Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD7503, Placebo

Sex

All

Actual Enrollment

56

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 06 Dec 2021
Primary Completion Date: 09 Nov 2022
Study Completion Date: 09 Nov 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria